John M S Bartlett
Overview
Explore the profile of John M S Bartlett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
10064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mukhtar R, Gottipati S, Yau C, Lopez-Tarruella S, Earl H, Hayward L, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):14.
PMID: 39948079
Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) is validated to predict event-free survival (EFS) in breast cancer but has not been studied for invasive lobular carcinoma (ILC). We studied...
2.
Karlsson P, Fyles A, Chang S, Arrick B, Baehner F, Malmstrom P, et al.
J Natl Cancer Inst
. 2024 Oct;
117(3):486-495.
PMID: 39423142
Background: There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene...
3.
Williams L, Kunkler I, Taylor K, Dunlop J, Piper T, Caldwell J, et al.
Lancet Oncol
. 2024 Aug;
25(9):1213-1221.
PMID: 39127062
Background: Breast-conserving surgery, adjuvant systemic therapy, and radiotherapy are the standard of care for most women with early breast cancer. There are few reports of clinical outcomes beyond the first...
4.
Chapman J, Bayani J, SenGupta S, Bartlett J, Piper T, Quintayo M, et al.
J Clin Oncol
. 2024 Jun;
42(24):2887-2898.
PMID: 38824432
Purpose: ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity...
5.
Senkin S, Moody S, Diaz-Gay M, Abedi-Ardekani B, Cattiaux T, Ferreiro-Iglesias A, et al.
Nature
. 2024 May;
629(8013):910-918.
PMID: 38693263
International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not yet been identified by conventional epidemiology make a substantial contribution to cancer...
6.
Bartlett J, Xu K, Wong J, Pond G, Zhang Y, Spears M, et al.
Clin Cancer Res
. 2024 Feb;
30(8):1509-1517.
PMID: 38345755
Purpose: Patients with early-stage hormone receptor-positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall...
7.
Ebrahimizadeh W, Guerard K, Rouzbeh S, Scarlata E, Brimo F, Patel P, et al.
Br J Cancer
. 2023 Apr;
128(12):2165-2174.
PMID: 37037938
Background: Distinguishing between true indolent and potentially life-threatening prostate cancer is challenging in tumours displaying clinicopathologic features associated with low or intermediate risk of relapse. Several somatic DNA copy number...
8.
Sgroi D, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, et al.
Breast Cancer Res
. 2022 Dec;
24(1):90.
PMID: 36527133
Background: Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET...
9.
Baez-Navarro X, Salgado R, Denkert C, Lennerz J, Penault-Llorca F, Viale G, et al.
Eur J Cancer
. 2022 Sep;
175:187-192.
PMID: 36137393
The promising effect of antibody-drug conjugates on breast cancer with low expression of HER2 (HER2-low) raises many questions regarding the optimal selection of patients for this treatment. A key question...
10.
Acs B, Leung S, Kidwell K, Arun I, Augulis R, Badve S, et al.
Mod Pathol
. 2022 Jun;
35(10):1362-1369.
PMID: 35729220
Ki67 has potential clinical importance in breast cancer but has yet to see broad acceptance due to inter-laboratory variability. Here we tested an open source and calibrated automated digital image...